| Literature DB >> 33143342 |
Marco Bonato1, Francesca Corrà1, Marta Bellio1, Laura Guidolin1, Laura Tallandini1, Paola Irato1, Gianfranco Santovito1.
Abstract
Due to their unique properties, perfluorinated substances (PFAS) are widely used in multiple industrial and commercial applications, but they are toxic for animals, humans included. This review presents some available data on the PFAS environmental distribution in the world, and in particular in Europe and in the Veneto region of Italy, where it has become a serious problem for human health. The consumption of contaminated food and drinking water is considered one of the major source of exposure for humans. Worldwide epidemiological studies report the negative effects that PFAS have on human health, due to environmental pollution, including infertility, steroid hormone perturbation, thyroid, liver and kidney disorders, and metabolic disfunctions. In vitro and in vivo researches correlated PFAS exposure to oxidative stress effects (in mammals as well as in other vertebrates of human interest), produced by a PFAS-induced increase of reactive oxygen species formation. The cellular antioxidant defense system is activated by PFAS, but it is only partially able to avoid the oxidative damage to biomolecules.Entities:
Keywords: antioxidant defenses; environmental pollution; epidemiology; human health; oxidative stress; perfluorinated substances; reactive oxygen species; toxicology
Mesh:
Substances:
Year: 2020 PMID: 33143342 PMCID: PMC7663035 DOI: 10.3390/ijerph17218020
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
A list of the most common perfluorinated substances (PFAS) with their applications and properties [31].
| PFAS | Use | Structure | Molecular Weight | Confirmed Toxic Effects |
|---|---|---|---|---|
| PFBA | synthetic chemistry |
| 214.04 | unknown |
| PFPeA | breakdown product of stain and grease-proof coatings on food packaging, couches, carpets |
| 264.05 | yes |
| PFHxA | unknown |
| 314.05 | yes |
| PFHpA | breakdown product of stain and grease-proof coatings on food packaging, couches, carpets |
| 364.06 | yes |
| PFOA | water and oil repellant in fabrics and textiles, food packaging |
| 414.07 | yes |
| PFNA | surfactant for synthesis of textiles and polymers |
| 464.08 | yes |
| PFDA | breakdown product of stain and grease-proof coatings on food packaging, couches, carpets |
| 514.08 | yes |
| PFUnA | unknown |
| 564.09 | yes |
| PFDoA | unknown |
| 614.1 | yes |
| PFBS | stain repellant |
| 300.1 | yes |
| PFHxS | surfactant for textiles |
| 400.11 | unknown |
| PFOS | firefighting foam, textiles |
| 500.13 | yes |
Figure 1Pathways of PFAS into the environment and their fate. Adapted from Ahrens [53]. STP = sewage treatment plant.
Figure 2Contaminated (in dark grey) and uncontaminated (in light grey) municipalities on the basis of the Italian National Health Institute (ISS) performance limits in drinking water in the Veneto region. In many municipalities (in white) no analyzes were carried out [120].
PFAS effects on human and other vertebrates.
| Species | PFAS | Effects | References |
|---|---|---|---|
|
| PFOA | Increased ROS formation 1, lipid peroxidation 2, GSH decrease 3, SOD induction 4, CAT induction 4, GPX inhibition 4, GR induction 4 | [ |
|
| PFOA | CAT inhibition 7, | [ |
|
| PFOS | Increased ROS formation 1, lipid peroxidation 2, | [ |
|
| PFOS | Increased ROS formation 1, lipid peroxidation 2, | [ |
|
| PFOS | Increased ROS formation 1, SOD induction 4, | [ |
|
| PFNA | Increased ROS formation 1 | [ |
|
| PFOA, PFNA | Lipid peroxidation 6, | [ |
|
| PFPiAs | [ | |
|
| PFOS | SOD induction 4 | [ |
|
| PFOA | [ | |
|
| PFOA | [ | |
|
| PFOA, PFOS | Increased ROS formation 1, apoptosis 11, | [ |
|
| PFHxS, PFOA, PFOS, PFNA, PFDA, PFUnA, PFDoA | Increased ROS formation 1, increased DNA damage 9, antioxidant defense inhibition 10 | [ |
|
| PFOA, PFOS | Estrogenicity and anti-estrogenicity 12 | [ |
|
| PFOA, PFOS, PFNA | Estradiol production 13, progesterone 13 production, testosterone production 13 | [ |
|
| PFOA, PFOS | Thyroid diseases | [ |
|
| PFOA, PFOS | Chronic kidney diseases | [ |
|
| PFHxS, PFOA, PFOS, PFNA | Decreased eGFR 14 | [ |
|
| PFHxs, PFOA, PFOS | Increased cholesterol outcomes 15 | [ |
|
| PFOA, PFOS, PFNA | Hyperglycemia 16, increased serum HDL | [ |
|
| PFOA, PFOS | Increased blood levels of glucocorticoid 17, | [ |
|
| PFOA, PFOS | Increased total adiponectin levels 19, | [ |
|
| PFHxS, PFHxA, PFHpA, PFOA, PFOS, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFTeDA | Allergic diseases | [ |
|
| PFOA, PFOS | Polyunsuturated fatty acids levels decrease 20, | [ |
|
| PFOA | Up-regulation of progesterone activated genes 5 | [ |
|
| PFOA, PFOS | Increased T4 levels 21 | [ |
|
| PFOA | Reduced fetal growth | [ |
|
| PFOA, PFOS | Reduced birth weight | [ |
|
| PFOA, PFOS | Reduced cord serum concentrations and | [ |
|
| PFOA, PFOS | Affected growth of organs and the skeleton | [ |
|
| PFBS, PFHxA, PFHpA, PFHxS, PFOA, PFOS, PFNA, PFDA, PFTA, PFDoA | Asthma | [ |
|
| PFHxS, PFOA, PFOS, PFNA | Asthma | [ |
|
| PFOA, PFOS | High insulin and trygliceride concentrations | [ |
|
| PFOA, PFOS, PFDeA | Changes in lipid profile 16, | [ |
|
| PFOA, PFOS, PFNA, PFHxS, PFDeA, PFOSA, Et-PFOSA, Me-PFOSA | Increased TSH22, increased eGFR 14 | [ |
|
| PFOA, PFOS | Reduced birth weight | [ |
|
| PFOA, PFOS | Increased cholesterol outcomes 16 | [ |
|
| PFOA, PFOS, PFNA, PFHxS | High serum cholesterol 16 | [ |
|
| PFOA, PFOS, PFNA, PFHxS | High serum cholesterol 16 | [ |
|
| PFOA | HNF4α inhibition 23, | [ |
|
| PFOS, PFOA, PFHxS, PFNA, PFDA | Potential diabetogenic effect | [ |
|
| PFOA, PFOS | Potential adiposity, decreased beta-cell function | [ |
|
| PFOA | Impaired platelet aggregation and increased cardiovascular risk | [ |
|
| PFPA, PFHpA, PFOA, PFUnA, PFDoA | Increased PPARα activity 24 | [ |
|
| PFOA, PFOS, PFHxS, PFHxA, PFNA, PFDA, PFBA, PFBS | Increased PPARα activity 24 | [ |
|
| PFOA, PFOS | Increased PPARα activity 24, increased PPARβ activity 24, increased PPARγ activity 24 | [ |
|
| PFOA, PFOS | Reduced birth weight | [ |
|
| PFOA, PFOS | Up-regulation of multiple nuclear | [ |
|
| PFOS | [ | |
|
| PFOA | Lipid peroxidation 25, amylase induction, lipase induction, | [ |
|
| PFOS | Increased in peroxisomal fatty acid beta-oxidation 4, increased peroxisomal catalase activity 4 | [ |
|
| PFOA | pparα up-regulation 5, pparγ up-regulation 5 | [ |
|
| PFOS | Serum testosterone decrease 19, epididymal sperm counts decrease, down-regulation of genes encoding testicular receptors for gonadotropin, growth hormone, insulin-like growth factor 1 and steroidogenic enzymes 5 | [ |
|
| PFOA | Damaged seminiferous tubules, reduced sperm quality, reduced serum testosterone and progesterone levels 13, INSL3 enzyme decrease 23, cytochrome P450 decrease 23 | [ |
|
| PFOS | Immune response induction 19 | [ |
|
| PFOA | CAT inhibition4 | [ |
|
| PFOA, PFOS | Increased ROS formation 1, lipid peroxidation 2, | [ |
|
| PFOA | SOD inhibition 4, CAT inhibition 4 | [ |
|
| PFOA | [ | |
|
| PFHxS, PFOS, PFDS, PFECHS, PFOA, PFNA, PFDA, PFUnA, PFDoA, PFTriA, PFTetraA | SOD induction 4, CAT induction 4, | [ |
|
| PFOA, PFOS | Lipid peroxidation 6 | [ |
|
| PFOA | Increased ROS formation 1, increased mithocondrial superoxide formation 25, increased nitric oxide formation 1, apoptosis 19, increased proinflammatory cytokines 19, reduced adenosine triphosphate levels 26, reduced cardiolipin peroxidation 27, reduced cytochrome c release 19 | [ |
|
| PFOA | Increased ACO activity 4, | [ |
|
| PFDoA | Serum testosterone decrease 19, serum estradiol decrease 19, down-regulation of genes involved in cholesterol transport and steroid biosynthesis 5 | [ |
|
| PFOA | Up-regulation of genes involved in metabolism of lipids, cell communication, growth, hormone regulatory pathways, proteolysis, peptidolysis and signal transduction 8, down-regulation of genes involved in inflammation and immunity, regulation of hormones, general metabolism and G-protein coupled receptor protein signaling pathways 8 | [ |
|
| PFOA, PFOS | [ | |
|
| PFASs | Increased levels of brain steroid hormones 28 | [ |
1 2′,7′-dichlorofluorescein deacetate; 2 malondialdehyde; 3 4-chloro-1-methyl-7-trifluoromethylquinolinium methylsulfate; 4 enzymatic activity; 5 quantitative real-time PCR; 6 thiobarbituric acid reactive species; 7 MALDI-TOF-TOF mass spectrometry; 8 microarray; 9 comet assay; 10 total antioxidant capacity; 11 FACSort flow cytometry; 12 E-SCREEN bioassay; 13 Coat-a-count radioimmunoassay; 14 serum creatinine; 15 Ortho VITROS Clinical Analyzer; 16 enzymatic assay; 17 immunoenzymometric assay; 18 liquid chromatography-tandem mass spectrometry; 19 Enzyme Linked ImmunoSorbent Assay; 20 gas chromatography-mass spectrometry; 21 AutoDELFIA fully automated system; 22 isometric assay; 23 Wester blotting; 24 transactivation assay; 25 MitoSOX™ Red mitochondrial superoxide indicator; 26 ATP colorimetric assay; 27 10-N-nonyl-Acridine Orange; 28 mass spectrometry.